USA - NASDAQ:ZNTL - US98943L1070 - Common Stock
Overall ZNTL gets a fundamental rating of 3 out of 10. We evaluated ZNTL against 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ZNTL as it has an excellent financial health rating, but there are worries on the profitability. ZNTL is valued expensive and it does not seem to be growing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.28% | ||
| ROE | -59.3% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.23 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.99 | ||
| Quick Ratio | 7.99 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ZNTL (10/30/2025, 11:21:07 AM)
1.525
-0.01 (-0.33%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.4 | ||
| P/tB | 0.4 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.28% | ||
| ROE | -59.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.99 | ||
| Quick Ratio | 7.99 | ||
| Altman-Z | -4.23 |
ChartMill assigns a fundamental rating of 3 / 10 to ZNTL.
ChartMill assigns a valuation rating of 0 / 10 to ZENTALIS PHARMACEUTICALS INC (ZNTL). This can be considered as Overvalued.
ZENTALIS PHARMACEUTICALS INC (ZNTL) has a profitability rating of 1 / 10.
The financial health rating of ZENTALIS PHARMACEUTICALS INC (ZNTL) is 7 / 10.
The Earnings per Share (EPS) of ZENTALIS PHARMACEUTICALS INC (ZNTL) is expected to grow by 3.31% in the next year.